TP53 and breast cancer: Consistent with the ex vivo findings, selective deletion of TP53 in fibroblasts, together with the expression of mutated oncogene KrasG12D (Box 2) in the epithelium, promoted the formation of mammary tumors in genetically modified mice by creating an immunosuppressive TME (Wu et al., 2022).